Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
125 hedge funds and large institutions have $313M invested in Keryx Biopharmaceuticals Inc in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 17 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 36
1.2% less ownership
Funds ownership: 65.42% → 64.22% (-1.2%)
3% less funds holding
Funds holding: 129 → 125 (-4)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
14% less capital invested
Capital invested by funds: $363M → $313M (-$49.7M)
42% less call options, than puts
Call options by funds: $2.65M | Put options by funds: $4.58M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.38M |
| 2 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$783K |
| 3 |
Goldman Sachs
New York
|
+$720K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$602K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$460K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$3.13M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.66M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.62M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$936K |
| 5 |
BA
Bristol Advisors
Conshohocken,
Pennsylvania
|
-$885K |
KERX Hedge Fund Activity: Q1 2018 in Review
125 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q1 2018, worth a combined $313M — down 14% from $363M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of KERX and 15 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 37 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $4.38M. The largest seller was State Street, cutting an estimated $3.13M.
- 125 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q1 2018, down from 129 in Q4 2017.
- Funds reported $313M of Keryx Biopharmaceuticals Inc stock for Q1 2018, down 14% quarter-over-quarter.
- 15 funds opened new Keryx Biopharmaceuticals Inc positions in Q1 2018 and 17 closed out, a net change of -2 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q1 2018 was Millennium Management, an estimated $4.38M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q1 2018 was State Street, an estimated $3.13M sold.
Based on aggregated 13F filings for Q1 2018.